FibroGen to Report Third Quarter 2025 Financial Results
FibroGen (NASDAQ: FGEN) will report its third quarter 2025 financial results on Monday, November 10, 2025 after market close. Management will host a conference call and live webcast the same day at 5:00 PM Eastern Time to discuss the results, provide a business update, and conduct a live Q&A session.
Investors can access a live audio webcast or register for phone dial-in details. A replay of the webcast will be available for a limited time on the company’s Events & Presentations page.
FibroGen (NASDAQ: FGEN) comunicherà i risultati finanziari del terzo trimestre 2025 lunedì 10 novembre 2025 dopo la chiusura del mercato. Il management terrà una conferenza telefonica e una webcast in diretta nello stesso giorno alle 17:00 ora orientale per discutere i risultati, fornire un aggiornamento sull'attività e condurre una sessione di domande e risposte in diretta.
Gli investitori potranno accedere a una webcast audio in diretta o registrarsi per i dettagli di dial-in telefonico. Una replica della webcast sarà disponibile per un periodo limitato sulla pagina Eventi e Presentazioni dell'azienda.
FibroGen (NASDAQ: FGEN) informará sus resultados financieros del tercer trimestre de 2025 el lunes 10 de noviembre de 2025 después del cierre del mercado. La dirección organizará una llamada de conferencia y webcast en vivo ese mismo día a 5:00 PM hora del este para discutir los resultados, ofrecer una actualización comercial y realizar una sesión de preguntas y respuestas en vivo.
Los inversionistas pueden acceder a un webcast de audio en vivo o registrarse para obtener los detalles de marcación telefónica. Una grabación del webcast estará disponible por un tiempo limitado en la página de Eventos y Presentaciones de la empresa.
FibroGen (NASDAQ: FGEN)은 2025년 11월 10일 월요일에 시장 마감 후 2025년 3분기 재무 실적을 발표합니다. 경영진은 같은 날 컨퍼런스 콜 및 라이브 웹캐스트를 미 동부 시간 17:00에 개최하여 결과를 논의하고, 비즈니스 업데이트를 제공하며, 라이브 Q&A 세션을 진행합니다.
투자자들은 라이브 오디오 웹캐스트에 접속하거나 전화 다이얼 인 정보를 등록할 수 있습니다. 웹캐스트의 재생은 회사의 Events & Presentations 페이지에서 제한된 기간 동안 이용 가능합니다.
FibroGen (NASDAQ: FGEN) annoncera ses résultats financiers du troisième trimestre 2025 le lundi 25 novembre 2025 après la clôture du marché. La direction organisera le même jour une conférence téléphonique et une webdiffusion en direct à 17h00, heure de l'Est pour discuter des résultats, fournir une mise à jour commerciale et assurer une session de questions-réponses en direct.
Les investisseurs peuvent accéder à une webdiffusion audio en direct ou s’inscrire pour obtenir les détails de connexion téléphonique. Une réécoute de la webdiffusion sera disponible pendant une période limitée sur la page Événements et Présentations de l’entreprise.
FibroGen (NASDAQ: FGEN) wird seine Ergebnisse des dritten Quartals 2025 am Montag, dem 10. November 2025 nach Börsenschluss bekannt geben. Das Management wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz und Live-Webcast abhalten, um die Ergebnisse zu besprechen, ein Geschäftupdate zu geben und eine Live-Q&A-Sitzung durchzuführen.
Investoren können auf einen Live-Audio-Webcast zugreifen oder sich für Telefondetails registrieren. Eine Wiedergabe des Webcasts wird für einen begrenzten Zeitraum auf der Seite des Unternehmens „Events & Presentations“ verfügbar sein.
FibroGen (NASDAQ: FGEN) ستعلن عن النتائج المالية للربع الثالث من عام 2025 يوم الاثنين 10 نوفمبر 2025 بعد إغلاق السوق. ستدير الإدارة مكالمة جماعية وبث حي مباشر في نفس اليوم في الساعة 5:00 مساءً بتوقيت شرق الولايات المتحدة لمناقشة النتائج، وتقديم تحديث للأعمال، ولعقد جلسة أسئلة وأجوبة مباشرة.
يمكن للمستثمرين الوصول إلى بث صوتي مباشر عبر الويب أو التسجيل للحصول على تفاصيل الاتصال الهاتفي. سيكون هناك تشغيل تكراري للبث متاح لفترة محدودة على صفحة فعاليات وعروض الشركة.
- None.
- None.
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on FibroGen’s website.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZOTM) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com
FAQ
When will FibroGen (FGEN) release its Q3 2025 earnings?
What time is the FibroGen (FGEN) Q3 2025 conference call and webcast?
How can investors join the FibroGen (FGEN) earnings webcast on November 10, 2025?
Will FibroGen (FGEN) provide a Q&A during the November 10, 2025 presentation?
Will a replay of the FibroGen (FGEN) November 10, 2025 webcast be available?
